

Marlies M Kok

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7229347/publications.pdf>

Version: 2024-02-01

30
papers

899
citations

567281

15
h-index

477307

29
g-index

34
all docs

34
docs citations

34
times ranked

1319
citing authors

#	ARTICLE	IF	CITATIONS
1	Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials. <i>International Journal of Cardiology</i> , 2021, 325, 37-44.	1.7	5
2	Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E188-E196.	1.7	6
3	Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials. <i>Cardiovascular Diabetology</i> , 2021, 20, 217.	6.8	11
4	Three-year clinical outcome in all-comers with silent diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drug-eluting stents: From the BIO-RESORT Silent Diabetes study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E110-E118.	1.7	8
5	New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials. <i>American Heart Journal</i> , 2020, 228, 109-115.	2.7	3
6	Involving the patient's perspective and preferences concerning coronary angiography and percutaneous coronary intervention. <i>EuroIntervention</i> , 2020, 15, 1228-1231.	3.2	4
7	Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1650-1660.	2.9	44
8	Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels. <i>JAMA Cardiology</i> , 2019, 4, 659.	6.1	56
9	5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 462-469.	2.9	41
10	Silent Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 448-459.	2.9	22
11	Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting Stents. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	5
12	Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial. <i>American Heart Journal</i> , 2018, 198, 25-32.	2.7	8
13	Serial assessment of endothelial function 1, 6, and 12 months after ST-elevation myocardial infarction. <i>Heart and Vessels</i> , 2018, 33, 978-985.	1.2	1
14	Patient preference for radial versus femoral vascular access for elective coronary procedures: The PREVAS study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 17-24.	1.7	75
15	Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. <i>Lancet</i> , The, 2018, 392, 1235-1245.	13.7	112
16	Are component endpoints equal? A preference study into the practice of composite endpoints in clinical trials. <i>Health Expectations</i> , 2018, 21, 1046-1055.	2.6	12
17	High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. <i>International Journal of Cardiology</i> , 2018, 268, 11-17.	1.7	19
18	High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 567-576.	2.6	7

#	ARTICLE	IF	CITATIONS
19	Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial. <i>EuroIntervention</i> , 2018, 14, 915-923.	3.2	38
20	Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients. <i>JAMA Cardiology</i> , 2017, 2, 268.	6.1	42
21	Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes. <i>Journal of Cardiology</i> , 2017, 69, 660-665.	1.9	25
22	Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents. <i>American Heart Journal</i> , 2016, 175, 121-129.	2.7	39
23	Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. <i>Lancet, The</i> , 2016, 388, 2607-2617.	13.7	208
24	Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 553-561.	2.9	18
25	Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial. <i>American Heart Journal</i> , 2016, 176, 28-35.	2.7	55
26	Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial. <i>Heart and Vessels</i> , 2016, 31, 1731-1739.	1.2	6
27	Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 206-215.	3.3	8
28	Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study. <i>EuroIntervention</i> , 2016, 11, 1487-1494.	3.2	3
29	TCT-570 3-Year Clinical Outcome of the DUTCH PEERS (TWENTE II) Randomized Trial: Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Versus Platinum-Chromium Everolimus-Eluting Promus Element Stents in All-Comer Patients. <i>Journal of the American College of Cardiology</i> , 2015, 66, B231.	2.8	0
30	Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial. <i>American Heart Journal</i> , 2015, 169, 69-77.	2.7	18